{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:11:38Z","timestamp":1790655098089,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41440-024-01733-4","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T04:01:34Z","timestamp":1716782494000},"page":"2133-2143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Esaxerenone: blood pressure reduction and cardiorenal protection without reflex sympathetic activation in salt-loaded stroke-prone spontaneously hypertensive rats"],"prefix":"10.1038","volume":"47","author":[{"given":"Shota","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyasu","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouji","family":"Matsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tsutsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Kinugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"1733_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","volume":"34","author":"NS Ferreira","year":"2021","unstructured":"Ferreira NS, Tostes RC, Paradis P, Schiffrin EL. Aldosterone, inflammation, immune system, and hypertension. Am J Hypertens. 2021;34:15\u201327.","journal-title":"Am J Hypertens"},{"key":"1733_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"1733_CR3","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","volume":"2","author":"K Ando","year":"2014","unstructured":"Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:944\u201353.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1733_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/10641963.2016.1246564","volume":"39","author":"L Liu","year":"2017","unstructured":"Liu L, Xu B, Ju Y. Addition of spironolactone in patients with resistant hypertension: a meta-analysis of randomized controlled trials. Clin Exp Hypertens. 2017;39:257\u201363.","journal-title":"Clin Exp Hypertens"},{"key":"1733_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijcard.2016.12.158","volume":"233","author":"D Zhao","year":"2017","unstructured":"Zhao D, Liu H, Dong P, Zhao J. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. Int J Cardiol. 2017;233:113\u20137.","journal-title":"Int J Cardiol"},{"key":"1733_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","volume":"761","author":"K Arai","year":"2015","unstructured":"Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol. 2015;761:226\u201334.","journal-title":"Eur J Pharmacol"},{"key":"1733_CR7","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/s41440-019-0314-7","volume":"42","author":"H Rakugi","year":"2019","unstructured":"Rakugi H, Ito S, Itoh H, Okuda Y, Yamakawa S. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens Res. 2019;42:1932\u201341.","journal-title":"Hypertens Res"},{"key":"1733_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","volume":"769","author":"K Arai","year":"2015","unstructured":"Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2015;769:266\u201373.","journal-title":"Eur J Pharmacol"},{"key":"1733_CR9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41440-018-0187-1","volume":"42","author":"L Li","year":"2019","unstructured":"Li L, Guan Y, Kobori H, Morishita A, Kobara H, Masaki T, et al. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats. Hypertens Res. 2019;42:769\u201378.","journal-title":"Hypertens Res"},{"key":"1733_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension. 2020;75:51\u20138.","journal-title":"Hypertension"},{"key":"1733_CR11","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/s41440-019-0270-2","volume":"42","author":"H Itoh","year":"2019","unstructured":"Itoh H, Ito S, Rakugi H, Okuda Y, Nishioka S. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study. Hypertens Res. 2019;42:1572\u201381.","journal-title":"Hypertens Res"},{"key":"1733_CR12","doi-asserted-by":"publisher","first-page":"e0259485","DOI":"10.1371\/journal.pone.0259485","volume":"16","author":"T Iwahana","year":"2021","unstructured":"Iwahana T, Saito Y, Okada S, Kato H, Ono R, Kobayashi Y. Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: a retrospective study. PLoS ONE. 2021;16:e0259485. https:\/\/doi.org\/10.1371\/journal.pone.0259485","journal-title":"PLoS ONE"},{"key":"1733_CR13","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41440-019-0211-0","volume":"42","author":"AS Bhuiyan","year":"2019","unstructured":"Bhuiyan AS, Rafiq K, Kobara H, Masaki T, Nakano D, Nishiyama A. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice. Hypertens Res. 2019;42:892\u2013902.","journal-title":"Hypertens Res"},{"key":"1733_CR14","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.3390\/ijms22042069","volume":"22","author":"A Rahman","year":"2021","unstructured":"Rahman A, Sawano T, Sen A, Hossain A, Jahan N, Kobara H, et al. Cardioprotective effects of a nonsteroidal mineralocorticoid receptor blocker, esaxerenone, in Dahl salt-sensitive hypertensive rats. Int J Mol Sci. 2021;22:2069. https:\/\/doi.org\/10.3390\/ijms22042069","journal-title":"Int J Mol Sci"},{"key":"1733_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1161\/01.HYP.0000158312.63381.c1","volume":"45","author":"Q Fu","year":"2005","unstructured":"Fu Q, Zhang R, Witkowski S, Arbab-Zadeh A, Prasad A, Okazaki K, et al. Persistent sympathetic activation during chronic antihypertensive therapy: a potential mechanism for long term morbidity? Hypertension. 2005;45:513\u201321.","journal-title":"Hypertension"},{"key":"1733_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/08037051.2012.690615","volume":"21","author":"CB Toal","year":"2012","unstructured":"Toal CB, Meredith PA, Elliott HL. Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS. Blood Press. 2012;21:3\u201310.","journal-title":"Blood Press"},{"key":"1733_CR17","doi-asserted-by":"publisher","first-page":"171s","DOI":"10.1042\/cs059171s","volume":"59","author":"R Dietz","year":"1980","unstructured":"Dietz R, Sch\u00f6mig A, Rascher W, Strasser R, K\u00fcbler W. Enhanced sympathetic activity caused by salt loading in spontaneously hypertensive rats. Clin Sci. 1980;59:171s\u20133s.","journal-title":"Clin Sci"},{"key":"1733_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1161\/01.HYP.4.6.773","volume":"4","author":"R Dietz","year":"1982","unstructured":"Dietz R, Sch\u00f6mig A, Rascher W, Strasser R, L\u00fcth JB, Ganten U, et al. Contribution of the sympathetic nervous system to the hypertensive effect of a high sodium diet in stroke-prone spontaneously hypertensive rats. Hypertension. 1982;4:773\u201381.","journal-title":"Hypertension"},{"key":"1733_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1440-1681.2007.04746.x","volume":"35","author":"W Zhang","year":"2008","unstructured":"Zhang W, Liu AJ, Yi-Ming W, Liu JG, Shen FM, Su DF. Pressor and non-pressor effects of sodium loading on stroke in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 2008;35:83\u20138.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1733_CR20","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1097\/HJH.0b013e328364a2a1","volume":"31","author":"N Honda","year":"2013","unstructured":"Honda N, Hirooka Y, Ito K, Matsukawa R, Shinohara K, Kishi T, et al. Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure. J Hypertens. 2013;31:2300\u20138.","journal-title":"J Hypertens"},{"key":"1733_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/ki.1984.147","volume":"26","author":"L Raij","year":"1984","unstructured":"Raij L, Azar S, Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int. 1984;26:137\u201343.","journal-title":"Kidney Int"},{"key":"1733_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1152\/advan.00027.2016","volume":"40","author":"RAL Dampney","year":"2016","unstructured":"Dampney RAL. Central neural control of the cardiovascular system: current perspectives. Adv Physiol Educ. 2016;40:283\u201396.","journal-title":"Adv Physiol Educ"},{"key":"1733_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1681\/ASN.2020071041","volume":"32","author":"N Ayuzawa","year":"2021","unstructured":"Ayuzawa N, Fujita T. The mineralocorticoid receptor in salt-sensitive hypertension and renal injury. J Am Soc Nephrol. 2021;32:279\u201389.","journal-title":"J Am Soc Nephrol"},{"key":"1733_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrneph.2013.110","volume":"9","author":"NJ Brown","year":"2013","unstructured":"Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013;9:459\u201369.","journal-title":"Nat Rev Nephrol"},{"key":"1733_CR25","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/nm.1879","volume":"14","author":"S Shibata","year":"2008","unstructured":"Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370\u20136.","journal-title":"Nat Med"},{"key":"1733_CR26","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00004872-200103001-00017","volume":"19","author":"Y Takeda","year":"2001","unstructured":"Takeda Y, Yoneda T, Demura M, Furukawa K, Miyamori I, Mabuchi H. Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats. J Hypertens. 2001;19:635\u20139.","journal-title":"J Hypertens"},{"key":"1733_CR27","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1124\/jpet.116.234765","volume":"358","author":"K Arai","year":"2016","unstructured":"Arai K, Morikawa Y, Ubukata N, Tsuruoka H, Homma T. CS-3150, a Novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate\/salt-induced hypertensive rats. J Pharmacol Exp Ther. 2016;358:548\u201357.","journal-title":"J Pharmacol Exp Ther"},{"key":"1733_CR28","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1291\/hypres.28.483","volume":"28","author":"H Kai","year":"2005","unstructured":"Kai H, Kuwahara F, Tokuda K, Imaizumi T. Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res. 2005;28:483\u201390.","journal-title":"Hypertens Res"},{"key":"1733_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1254\/jjp.66.231","volume":"66","author":"T Fujiwara","year":"1994","unstructured":"Fujiwara T, Yuasa H, Ogiku N, Kawai Y. Histopathological investigation on salt-loaded stroke-prone spontaneously hypertensive rats, whose biochemical parameters of renal dysfunction were ameliorated by administration of imidapril. Jpn J Pharmacol. 1994;66:231\u201340.","journal-title":"Jpn J Pharmacol"},{"key":"1733_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","volume":"65","author":"J Bauersachs","year":"2015","unstructured":"Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65:257\u201363.","journal-title":"Hypertension"},{"key":"1733_CR31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s10286-005-0290-7","volume":"15","author":"EE Benarroch","year":"2005","unstructured":"Benarroch EE. Paraventricular nucleus, stress response, and cardiovascular disease. Clin Auton Res. 2005;15:254\u201363.","journal-title":"Clin Auton Res"},{"key":"1733_CR32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrn1902","volume":"7","author":"PG Guyenet","year":"2006","unstructured":"Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7:335\u201346.","journal-title":"Nat Rev Neurosci"},{"key":"1733_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1681\/ASN.2012070678","volume":"24","author":"J Kim","year":"2013","unstructured":"Kim J, Padanilam BJ. Renal nerves drive interstitial fibrogenesis in obstructive nephropathy. J Am Soc Nephrol. 2013;24:229\u201342.","journal-title":"J Am Soc Nephrol"},{"key":"1733_CR34","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/ki.2014.300","volume":"87","author":"J Kim","year":"2015","unstructured":"Kim J, Padanilam BJ. Renal denervation prevents long-term sequelae of ischemic renal injury. Kidney Int. 2015;87:350\u20138.","journal-title":"Kidney Int"},{"key":"1733_CR35","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1146\/annurev-physiol-031620-091656","volume":"83","author":"JW Osborn","year":"2021","unstructured":"Osborn JW, Tyshynsky R, Vulchanova L. Function of renal nerves in kidney physiology and pathophysiology. Annu Rev Physiol. 2021;83:429\u201350.","journal-title":"Annu Rev Physiol"},{"key":"1733_CR36","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1097\/HJH.0b013e328338bb37","volume":"28","author":"K Ito","year":"2010","unstructured":"Ito K, Hirooka Y, Sunagawa K. Blockade of mineralocorticoid receptors improves salt-induced left-ventricular systolic dysfunction through attenuation of enhanced sympathetic drive in mice with pressure overload. J Hypertens. 2010;28:1449\u201358.","journal-title":"J Hypertens"},{"key":"1733_CR37","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/hr.2011.220","volume":"35","author":"T Nakagaki","year":"2012","unstructured":"Nakagaki T, Hirooka Y, Matsukawa R, Nishihara M, Nakano M, Ito K, et al. Activation of mineralocorticoid receptors in the rostral ventrolateral medulla is involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats. Hypertens Res. 2012;35:470\u20136.","journal-title":"Hypertens Res"},{"key":"1733_CR38","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/hr.2012.174","volume":"36","author":"M Nakano","year":"2013","unstructured":"Nakano M, Hirooka Y, Matsukawa R, Ito K, Sunagawa K. Mineralocorticoid receptors\/epithelial Na(+) channels in the choroid plexus are involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats. Hypertens Res. 2013;36:277\u201384.","journal-title":"Hypertens Res"},{"key":"1733_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41440-019-0333-4","volume":"43","author":"T Iyonaga","year":"2020","unstructured":"Iyonaga T, Shinohara K, Mastuura T, Hirooka Y, Tsutsui H. Brain perivascular macrophages contribute to the development of hypertension in stroke-prone spontaneously hypertensive rats via sympathetic activation. Hypertens Res. 2020;43:99\u2013110.","journal-title":"Hypertens Res"},{"key":"1733_CR40","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1536\/ihj.23.593","volume":"23","author":"S Maemura","year":"1982","unstructured":"xMaemura S, Niwa M, Ozaki M. Characteristic alterations in adrenal catecholamine contents in SHR, SHRSP, and WKY during development of hypertension and stroke. Jpn Heart J. 1982;23:593\u2013602.","journal-title":"Jpn Heart J"},{"key":"1733_CR41","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1111\/jch.14334","volume":"23","author":"K Katsurada","year":"2021","unstructured":"Katsurada K, Kario K. Sympathetic modulation by antihypertensive drugs. J Clin Hypertens. 2021;23:1715\u20137.","journal-title":"J Clin Hypertens"},{"key":"1733_CR42","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/ajh\/hpaa074","volume":"33","author":"Y Hirooka","year":"2020","unstructured":"Hirooka Y. Sympathetic activation in hypertension: importance of the central nervous system. Am J Hypertens. 2020;33:914\u201326.","journal-title":"Am J Hypertens"},{"key":"1733_CR43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1152\/physrev.00007.2009","volume":"90","author":"SC Malpas","year":"2010","unstructured":"Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev. 2010;90:513\u201357.","journal-title":"Physiol Rev"},{"key":"1733_CR44","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1161\/CIRCRESAHA.114.302524","volume":"114","author":"G Mancia","year":"2014","unstructured":"Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114:1804\u201314.","journal-title":"Circ Res"},{"key":"1733_CR45","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/s41440-020-0495-0","volume":"43","author":"K Arai","year":"2020","unstructured":"Arai K, Morikawa Y, Ubukata N, Sugimoto K. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker. Hypertens Res. 2020;43:1204\u201313.","journal-title":"Hypertens Res"},{"key":"1733_CR46","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/s41440-023-01292-0","volume":"46","author":"K Kario","year":"2023","unstructured":"Kario K, Nishizawa M, Kato M, Ishii H, Uchiyama K, Nagai M, et al. Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study. Hypertens Res. 2023;46:1782\u201394.","journal-title":"Hypertens Res"},{"key":"1733_CR47","doi-asserted-by":"publisher","unstructured":"Katsuya T, Inobe Y, Uchiyama K, Nishikawa T, Hirano K, Kato M, et al. Exploratory study on the relationship between urinary sodium\/potassium ratio, salt intake, and the antihypertensive effect of esaxerenone: the ENaK Study. Hypertens Res. 2024. https:\/\/doi.org\/10.1038\/s41440-023-01519-0","DOI":"10.1038\/s41440-023-01519-0"},{"key":"1733_CR48","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/s41440-022-00913-4","volume":"45","author":"M Mogi","year":"2022","unstructured":"Mogi M. Aldosterone breakthrough from a pharmacological perspective. Hypertens Res. 2022;45:967\u201375.","journal-title":"Hypertens Res"},{"key":"1733_CR49","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/ajh\/hpt188","volume":"27","author":"T Kishi","year":"2014","unstructured":"Kishi T, Hirooka Y, Sunagawa K. Telmisartan reduces mortality and left ventricular hypertrophy with sympathoinhibition in rats with hypertension and heart failure. Am J Hypertens. 2014;27:260\u20137.","journal-title":"Am J Hypertens"},{"key":"1733_CR50","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1152\/physiolgenomics.00068.2004","volume":"18","author":"AK Siegel","year":"2004","unstructured":"Siegel AK, Kossmehl P, Planert M, Schulz A, Wehland M, Stoll M, et al. Genetic linkage of albuminuria and renal injury in Dahl salt-sensitive rats on a high-salt diet: comparison with spontaneously hypertensive rats. Physiol Genomics. 2004;18:218\u201325.","journal-title":"Physiol Genomics"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01733-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01733-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01733-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T08:04:02Z","timestamp":1723104242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01733-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1733"],"URL":"https:\/\/doi.org\/10.1038\/s41440-024-01733-4","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"28 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KS reports grants from Daiichi Sankyo, Nippon Boehringer Ingelheim, and Otsuka Medical Devices. HT reports grants and\/or personal fees from Daiichi Sankyo, Novartis Pharma, Otsuka Pharmaceutical, Pfizer Japan, Mitsubishi Tanabe Pharma, Teijin Pharma, Nippon Boehringer Ingelheim, AstraZeneca, Ono Pharmaceutical, Kowa, IQVIA Service Japan, MEDINET, Medical Innovation Kyushu, Bayer Yakuhin, Johnson & Johnson, NEC, Nippon Rinsho and Japanese Heart Failure Society. The other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}